Severe chronic periodontitis is not common in Acromegaly: Potential protective role of gingival BMP-2

Sibel BAŞÇIL¹, Özlem TURHAN İYİDİR²*, Nilüfer BAYRAKTAR³, Melek Eda ERTÖRER⁴, Neslihan BAŞÇIL TÜTÜNCÜ⁵

¹Department of Periodontology, Faculty of Dentistry, Başkent University, Adana, Turkey
²Department of Endocrinology and Metabolism, Faculty of Medicine, Başkent University, Ankara, Turkey
³Department of Biochemistry, Faculty of Medicine, Başkent University, Ankara, Turkey

Background/aim : Advanced chronic periodontitis is observed rarely in acromegaly. Periodontal tissue including the alveolar bone is seemed to be spared from the systemic metabolic derangements of bone in this patient population. Chronic elevation of growth hormone, IGF-1, and bone morphogenetic proteins may play a role in periodontal tissue regeneration in acromegals. In this study, we aimed to evaluate the potential roles of local gingival bone morphogenetic proteins (BMP) in periodontal tissue pathology in acromegaly.

Materials and methods: Thirty-five patients with acromegaly and 22 healthy subjects were recruited. All the participants were examined by the same periodontologist for the diagnosis of periodontal diseases. BMP-2 and -4 were studied in gingival crevicular fluid.

Results: Gingival BMP-2 and BMP-4 levels were similar in acromegaly and control groups in general, with and without chronic periodontitis. For all the participants, gingival BMP-2 levels were statistically lower in those participants with chronic periodontitis than those without periodontitis (29.4 ± 11.2 vs. 41.2 ± 23.2, respectively, p = 0.027). Causal relation between the gingival BMP levels and periodontal tissue health status was tested with one way ANOVA which revealed a significant difference between gingival BMP-2 levels in those with different degrees of periodontal tissue pathology (p = 0.025). When analyzed separately, gingival BMP-2 levels revealed a causal relation with the degree of periodontal pathology with borderline significance only in patients with acromegaly (p = 0.057).

Conclusion: Acromegaly is a disease with an unexpectedly low frequency of advanced periodontitis, irrespective of the long disease duration and pathognomonic oral manifestations. BMP-2 might have a protective role against chronic advanced periodontitis in these patients.

Key words: Acromegaly, periodontitis, growth hormone, bone morphogenetic protein-2, bone morphogenetic protein-4

1. Introduction:
Acromegaly is among the rare diseases with complex effects on bone remodelling. Uncontrolled secretion of growth hormone (GH) from the hypophysis is the key feature of acromegaly, whereas elevated levels of insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 and calcitriol, and the presence or absence of secondary gonadal insufficiency are important factors that influence the bone metabolism in these patients (1). Duration of disease activity and remission are also important determinants of the final bone health (2).

Acromegaly has important pathognomonic oral features of prognathism, macroglossia, increased interdental spaces, and dental mobility (3). Although its typical characteristics are well known, periodontitis is unexpectedly rare, as demonstrated in some of the recent studies (4,5). Likewise in our previous study, we found that chronic periodontitis was not encountered more frequently, then the age and sex matched population and even surprisingly the advanced from of it was less commonly observed in acromegalic patients (6).

Alveolar bone metabolism and thus, periodontal tissue seems to be spared or less affected by the complex influencing factors in acromegaly. Growth factors like GH, IGF-1, and GH-mediated local growth factors like bone morphogenetic proteins (BMPs) may play roles in periodontal tissue regeneration in this patient population. GH and IGF-1 are known to increase the formation of bone and hard tissues of the tooth (dentine, cementum, and enamel) (7). GH receptors are expressed in these
tissues and can mediate local growth responses. There are few reports demonstrating the stimulation of bone morphogenetic protein-2 and -4 mRNA expression by GH and IGF-1 up to 4- to 5-fold in human dental pulp fibroblasts in vitro (8). BMP play an important role in periodontal tissue regeneration both in fetal life and in adults (9). The therapeutic use of recombinant BMPs like recombinant human (rh) BMP-2 has attracted considerable interest in the treatment of various periodontal diseases due to the potent ability of these factors to stimulate intramembranous bone formation without an endochondral intermediate (10).

In our present study, we hypothesized that the excess of GH/IGF-1 affects directly or indirectly the bone remodelling of the periodontal tissue in acromegaly patients. Long-standing GH/IGF-1 excess, by increasing the local tissue BMP levels, might influence positively the regenerative capacity of the periodontal tissue in this patient group. In this context, we aimed to determine BMP-2 and BMP-4 levels in the gingival fluid to find any association with the health status of the periodontal tissue in those with acromegaly.

2. Materials and methods

2.1. Study Subjects
We enrolled 35 acromegalic patients from the outpatient clinic of the Endocrinology Department at Başkent University Faculty of Medicine, consequently, between September 2010 and July 2013. The diagnosis of acromegaly was established clinically and confirmed by high serum GH concentrations that were not suppressed after oral glucose tolerance test (75 gr), elevated IGF-1 levels for age and sex, and demonstration of the pituitary tumor by computed tomographic scan or magnetic resonance imaging. Duration of the disease, history of pituitary surgery and radiotherapy, activity of the disease, treatment with a somatostatin analogue, and length of remission were recorded. A total of 22 otherwise healthy participants were enrolled for oral examination to assess periodontal tissue health and gingival BMP measurement. Exclusion criteria were history of chronic renal failure, hyperparathyroidism, hyperthyroidism, and active smoking, which may all influence bone metabolism and periodontal tissue. Informed written consent was obtained from all subjects prior to their enrollment, and our local ethics committee approved the study protocol (tracking number KA08/104).

2.2. Periodontal assessment
Individuals from both groups were asked to fill a questionnaire about oral hygiene and frequency of annual check-up and/or regular dental visits.

All of the study subjects were examined by the same experienced periodontist. Periodontal pocket depth (presence of an abnormal gingival sulcus near the point at which the gums contact a tooth) was evaluated using periodontal probe at six different points of each tooth. Individuals with probing pocket depth (PPD) between 4-6 mm and clinical attachment level (CAL = amount of space between attached periodontal tissues and a fixed point, usually the cementoenamel junction) up to 4 mm were considered as chronic periodontitis with slight to moderate loss of periodontal support [15]. Those with PPD ≥ 6 mm and CAL greater than 4 mm were considered as chronic periodontitis with advanced loss of periodontal support (16). Bleeding on probing, which was considered an objective inflammatory parameter in periodontitis establishment, was measured using gingival bleeding index (GBI) (17). Gingival bleeding index ≤0.1 was considered as low risk for the development of periodontitis. Tooth mobility levels were evaluated and classified as degrees 1, 2, and 3. Radiographic examinations, tooth loss, diastemas (space or gap between two teeth), and malocclusion were also assessed.

2.3. Endocrinological assessment
Clinical data of acromegalic patients were evaluated and assessed by the same experienced endocrinologist. The estimated duration of the disease was determined according to the clinical history and review of the past photographs of the patients. The disease activity was assessed by GH suppression during OGTT. Hormonal status of anterior hypophysis was analysed by both basal serum pituitary hormone levels (ACTH, PRL, FSH, LH, TSH) with their end organ hormones and dynamic tests. Disease was considered cured when all these criteria were met: Random GH level less than 2.5 mg/L, plasma IGF-1 levels normal for the patient's age, GH suppressed during OGTT, and the patient is not taking any somatostatine analog. Disease was defined as inactive when random GH level was less than 2.5 mg/L, and plasma IGF-1 levels were normal for the patient's age under a somatostatin analog.

2.4. Biochemical assessment
Serum levels of GH, IGF-1, and IGFBP-3 were determined by commercially available kits: chemiluminescent enzyme immunometric assay for GH (Immulite Growth Hormone, Diagnostic Products Corp., CA, USA), immunoradiometric assay (Diagnostic Systems Laboratories, DSL-6600 ACTIVE) for IGFBP-3, highly sensitive and specific immunoradiometric assay, which uses a modified version of the standard acid-ethanol extraction procedure (Diagnostic Systems Laboratories, DSL-5600 ACTIVE) for plasma IGF-1.

The levels of BMP-2, and -4 in GCF samples were assayed using sandwich ELISA method (Aviscera Bioscience Inc., Santa Clara, CA, USA). All ELISA procedures were carried out according to the manufacturer's instructions. Microcentrifuge tubes, containing a PerioPaper strip,
with absorbed gingival crevicular fluid (GCF) sample, were removed from storage and warmed to +4 °C, and then eluted using a centrifuge. The microcentrifuge tubes containing the strips and the dilution buffer were vortexed for 1 min and incubated overnight at +4 °C. The next morning, samples were vortexed for 3 min at room temperature. After the centrifugation at 1000 g 20 min, the strips were removed and the fluid was assayed by ELISA for BMP-2 and BMP-4. The ELISA plates were then assessed spectrophotometrically for their optical density (OD) at an absorbance of 450 nm. The levels of BMP-2 and BMP-4 in each GCF sample were determined using the concentration values of the standards included in the kit. The detection limits were as follows; BMP2 < 46.87 pg/mL, BMP-4 < 3.9 pg/mL. The intra- and inter-assay variabilities were 4%–6% and 8%–12% for BMP-2 and BMP-4, respectively.

Statistical analysis: Descriptive statistics for the study group are expressed as mean ± standard deviation for continuous variables and as proportions for ordinal (categoric) variables, such as sex, radiotherapy, presence of periodontitis, and malocclusion. Differences within patient clinical characteristics, BMP levels, and comparisons with the healthy control group were evaluated for statistical significance using the Student’s t-test and the Chi-square method where appropriate. Comparison of nonparametric groups (acromegaly disease duration) was analysed by using Mann–Whitney U test. Assumption of equal group variances for continuous variables were tested by Levene’s tests for Students t- test. To test the effect of gingival BMP levels on the severity of periodontal disease, one way ANOVA test was conducted. Assumption of equal group variances was tested by posthoc Bonferroni and Dunnett tests. Statistical significance was considered when a two-sided p value was 0.05 or below. For statistical analysis, Predictive Analytics Software (PASW-Release 18) statistical software was used.

3. Results:
A total of 35 acromegalic patients with a mean age of 46.7 ± 10.2 years, and 22 otherwise healthy control volunteers with a mean age of 42.4 ± 4.2 years were included in the study. All of the acromegalic patients underwent pituitary surgery and 15 patients received radiotherapy. Twenty-nine of the acromegalic patients were under somatostatin analog treatment. Twelve of the acromegalic patients had inactive or cured disease, 23 patients had active disease. There was only one patient whose disease was cured.

The clinical characteristics and the gingival BMP levels of the study participants are given in Table 1. The acromegaly group and the healthy volunteers were matched with respect to age but the proportion of females was higher in the healthy control group (p = 0.034). About 45.7% of the acromegalic patients had pathognomonic acromegalic oral features like macroglossia, prognatism, and/or malocclusion. Diabetes or prediabetes was encountered in 11 of the acromegaly patients.

Table 1. Clinical characteristics and the gingival BMP levels of the study participants.

|                            | Acromegaly patients (n = 35) | Healthy control group(n = 22) | P      |
|---------------------------|------------------------------|-------------------------------|--------|
| Age (years)               | 46.7 ± 10.2                  | 42.4 ± 4.2                    | NS*    |
| Sex (F/M)                 | 21/14                        | 19/3                          | 0.034**|
| Acromegaly disease duration | 6.87 ± 3.2                   | -                             | -      |
| Diabetes/prediabetes mellitus | 11 (31.4%)               | -                             | -      |
| Primary or secondary hypogonadism | 6 (17.1%)               | -                             | -      |
| Secondary hypothyroidism | 2 (5.7%)                     | -                             | -      |
| Typical acromegalic oral features | 16 (45.7 %)                     | -                             | -      |
| Macroglossia/prognathism/malocclusion | 16 (45.7 %)                     | -                             | -      |
| Chronic periodontitis (any degree) (n,%), | 16 (45.7%)                  | 5(22.7%)                      | 0.043**|
| Advanced chronic periodontitis (n,%), | 2 (5.7 %)                     | 1 (4.5%)                      | NS**   |
| Chronic periodontitis (any degree) in females (n,%), | 9 (42.8%)                   | 4 (21.9%)                     | NS**   |
| Chronic periodontitis (any degree) in males (n,%), | 7 (50%)                     | 1 (33.3%)                     | NS**   |
| Gingival BMP2 (pg/mL)     | 33.5 ± 20.4                  | 39.2 ± 17.4                   | NS*    |
| Gingival BMP4 (pg/mL)     | 36.4 ± 26.4                  | 29.9 ± 14.6                   | NS*    |

NS = nonsignificant, BMP2: Bone morphogenetic protein-1; BMP4: Bone morphogenetic protein-4. ‘Student’s t test, ** Chi Square test
Hypogonadism was diagnosed in 6 of the acromegalics, 4 of which were secondary and 2 were primary hypogonadism cases. Secondary hypothyroidism was present in 2 of the acromegalics, while there was no patient with primary hypothyroidism. Frequency of chronic periodontitis was higher in acromegalics, advanced periodontitis cases were similar in number in both groups (5.7% vs. 4.5%; p > 0.05) (Table 1). In real life generally and in case of our present study, females have better oral hygiene (as noted from questionnaire about oral hygiene and frequency of annual check-up and/or regular dental visits in our study). Hence the predominance of females in the healthy control group have biased the results of our study. Male abundance and the frequent periodontitis in males in acromegalics (50%) increased the total cases with periodontitis in the acromegaly group in the present study. When the groups were matched with sex, the females and males in both groups of study participants revealed similar frequency of periodontitis (Table 1). There was also no increase in the frequency of any degree of periodontitis cases even in those with robust manifestations of pathognomonic oral features of acromegaly such as macroglossia, prognathism, and/or malocclusion. Gingival BMP-2 and BMP-4 levels were similar in the acromegaly and control groups (Table 1).

Plasma IGF-1, GH and IGFBP-3, and gingival BMP levels according to the disease activity in the acromegaly group are given in Table 2. Both gingival BMP-2 and BMP-4 levels were similar in those with active and inactive acromegalics. Plasma GH, IGF-1, and IGFBP-3 levels were statistically high, as expected, in those acromegalics with active disease. There were 23 acromegalics with active GH secretion with a median disease duration of 4.5 years (interquartile range Q3-Q1 = 5.5 years). Median duration of acromegaly was 8 years (interquartile range Q3-Q1 = 4 years) in those with inactive disease. The duration of acromegaly was statistically longer in those with inactive disease (p = 0.01) (Table 2). Total duration of disease inactivity was minimum 6 months and maximum of about 3 years for these patients at the time of study enrollment. Disease duration and duration of disease inactivity did not correlate with the gingival BMP levels.

Frequency of chronic periodontitis and gingival BMP levels were similar in acromegalics regardless of disease activity at the time of study enrollment. Likewise, presence of diabetes or prediabetes, nor the hypogonadism influenced the periodontal tissue health in our patient population.

Table 3 gives the gingival BMP levels according to periodontal tissue health. When those with and without chronic periodontitis were subgrouped, gingival BMP-2 levels were statistically lower in those participants with chronic periodontitis then those without periodontitis (29.4 ± 11.2 vs. 41.2 ± 23.2, respectively, p = 0.027). Gingival BMP-4 levels were similar in those with and without periodontitis.

When the acromegalics and healthy controls with and without chronic periodontitis were analysed separately,

**Table 2.** Gingival BMP levels according to disease activity of the acromegaly group.

|                               | Acromegaly patients with active disease (high GH/IGF-1 levels) (n = 23) | Acromegaly patients with inactive disease (normal GH/IGF-1 levels) (n = 12) | P    |
|-------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|------|
| GH (ng/mL)                    | 7.4 ± 3.1                                                              | 2.4 ± 0.2                                                                | 0.003* |
| IGF-1 (ng/mL)                 | 411.0 ± 129.5                                                           | 245.9 ± 31.7                                                             | 0.008* |
| IGFBP-3 (ng/mL)               | 4178.3 ± 1086.8                                                         | 2056.0 ± 393.7                                                           | 0.004* |
| Disease duration (years)      | Median 4.5 IQR: 5.5                                                     | Median 8 IQR: 4                                                          | 0.01* |
| Presence of diabetes/prediabetes | 5/23 (21.7%)                                                           | 4/12 (33.3%)                                                            | NS   |
| Presence of hypogonadism      | 4/23 (17.4%)                                                            | 2/12 (16.6%)                                                            | NS   |
| Presence of typical oral features (macroglossia/prognathism/malocclusion) | 10/23 (43.4%)                                                          | 6/12 (50%)                                                              | NS   |
| Chronic periodontitis of any degree | 10/23                                                                 | 6/12                                                                    | NS   |
| Gingival BMP2(pg/mL)          | 26.6 ± 14.7                                                             | 40.3 ± 28.2                                                             | NS   |
| Gingival BMP4(pg/mL)          | 37.7 ± 37.6                                                             | 34.0 ± 14.7                                                             | NS   |

NS = nonsignificant BMP1: Bone mophogenetic protein 1 (pg/mL); BMP2: Bone morphogenetic protein 2 (pg/mL); GH: Growth hormone; IGF-1: Insulin like growth factor -1; IGFBP-3: Insulin like growth factor binding protein-3; IQR: Interquartile ratio (Q3-Q1); *Student’s t test; ** Chi Square test, + Mann–Whitney U test.
both the acromegals and the healthy control group, revealed similar gingival BMP-2 and BMP-4 levels.

Table 4 summarizes the relation of gingival BMP levels with the periodontal tissue health status in acromegals and the control group. Causal relation between the gingival BMP levels and periodontal tissue health status was tested with one way ANOVA, which revealed a significant difference between gingival BMP-2 levels in those with different degrees of periodontal tissue pathology (p = 0.025). When analyzed separately, gingival BMP-2 levels revealed a causal relation with the degree of periodontal pathology with borderline significance only in patients with acromegaly (p = 0.057). As the gingival BMP2 levels decreased, periodontal pathology tended to advance to higher degrees in severity (Table 4 and Figure). No significant correlation existed between gingival BMP-4 level and periodontal tissue pathology in the acromegals. Likewise, neither the gingival BMP-2 nor the BMP-4 levels had been found to be correlated with the periodontal pathology in the healthy controls (Table 4).

4. Discussion

In the previous studies exploring periodontal pathologies in acromegaly, periodontitis was found to be unexpectedly rare in these patients (6,12). In our present study, however, when both males and females were analysed together, periodontitis was found to be more frequent in the acromegaly group. Most probably, the female predominance in the control group might have biased the result. After matching the study participants with respect to sex, we found a similar frequency of chronic periodontitis in the acromegaly and the control groups. Although the typical oral manifestations like macroglossia, prognathism, and malocclusion were encountered in almost half of our acromegaly patients in the present study, the occurrence, frequency, and grade of periodontitis

| Table 3. Gingival BMP levels in subgroups of study participants. |
|---------------------------------------------------------------|
|Participants with chronic periodontitis (n = 21) | Participants without periodontitis (n = 36) | p |
|Gingival BMP2 (pg/mL) | 29.4 ± 11.2 | 41.2 ± 23.2 | 0.027* |
|Gingival BMP4 (pg/mL) | 37.3 ± 5.8 | 30.9 ± 6.7 | NS |
|Acromegaly group: | | | |
|Acromegaly patients with chronic periodontitis (n = 16) | Acromegaly patients without chronic periodontitis (n = 19) |
|Gingival BMP2 (pg/mL) | 28.1 ± 11.6 | 39.9 ± 26.8 | NS |
|Gingival BMP4 (pg/mL) | 41.4 ± 34.2 | 31.8 ± 17.9 | NS |
|Control group: | | | |
|Healthy controls with chronic periodontitis (n = 5) | Healthy controls without chronic periodontitis (n = 17) |
|Gingival BMP2 (pg/mL) | 33.5 ± 9.9 | 40.9 ± 9.9 | NS |
|Gingival BMP4 (pg/mL) | 24.1 ± 10.7 | 31.6 ± 15.4 | NS |

*Student's t test.

| Table 4. One way ANOVA test results of the effect of gingival BMP2 levels on the severity of periodontitis in acromegaly patients and the healthy controls. |
|---------------------------------------------------------------|
| All participants (n = 57) | |
| | No periodontitis | Mild to moderate periodontitis | Severe periodontitis | p |
|Mean Gingival BMP2 levels (pg/mL) | 41.3 ± 22.2 | 29.3 ± 9.4 | 20.8 ± 8.2 | 0.025 |
|Acromegaly patients (n = 35) | | | | |
|Mean Gingival BMP2 levels (pg/mL) | 41.7 ± 25.6 | 27.7 ± 8.6 | 17.7 ± 5.1 | 0.057 |
|Healthy controls (n = 22) | | | | |
|Mean Gingival BMP2 levels (pg/mL) | 40.9 ± 18.9 | 33.5 ± 11.4 | 33.2 | NS |

NS: nonsignificant
In our present study, although the gingival BMP2 levels tend to be higher in those with healthier periodontal tissue, gingival BMP-2 and BMP-4 levels were similar in the active and inactive acromegaly patients. Total acromegaly disease duration and duration of the inactive acromegaly period did not show any effect on the gingival BMP levels in the present study. However, this finding should be interpreted cautiously. Since acromegaly has a significant diagnostic delay in almost all patients (15), the duration of disease calculated from the time of biochemical diagnosis usually does not reflect exactly the actual cumulative exposure of tissues to the GH excess. Further prospective studies evaluating the periodontal status of patients with acromegaly may extend our knowledge on this issue.

The relatively small sample size and the cross-sectional nature of our study are its major limitations. Considering this, and the fact that acromegaly is a very rare disease with a prevalence of 50–70 cases per million, it is usually hard to evaluate large numbers of cases in a single centre. We recruited the acromegaly patients and controls that we could reach from our acromegaly pool of hospital and get informed consent. We are also aware of the possible selection bias both in acromegalics and control subjects, which may not truly reflect the reality and thus, does not allow to make solid conclusions about the protective role of local gingival BMP levels in acromegaly patients.
In conclusion, acromegaly is a disease with an unexpectedly low frequency of severe to advanced periodontal pathology, irrespective of the long disease duration and pathognomonic oral manifestations. Although we could not find any differences in local gingival BMP-2 and BMP-4 levels between patients in the acromegaly and control groups, the unexpectedly low frequency of severe periodontitis and the finding of increasing levels of gingival BMP-2 levels as the degree of periodontal tissue problem decreases in acromegals, suggested a protective role for BMP-2 in acromegals. As the gingival BMP2 levels decreased, periodontal pathology tended to advance to higher degrees in severity. To the best of our knowledge, this is the first study evaluating BMP-2 and -4 levels in the gingival fluid of patients with acromegaly. Our study is a pilot study and forms basis for further studies with larger sample sizes to evaluate the local regenerative and/or destructive processes and factors influencing the periodontal tissue biology in acromegaly patients.

References

1. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP. Gonadal status is an important determinant of bone density in acromegaly. Clinical Endocrinology (Oxf.) 1998; 48 (1): 59-65 DOI: 10.1046/j.1365-2265.1998.00349.x

2. Fredstorp L, Pernow Y, Werner S. The short and long-term effects of octreotide on calcium homeostasis in patients with acromegaly. Clinical Endocrinology (Oxf.) 1993; 39 (3): 331-336 DOI: 10.1111/j.1365-2265.1993.tb02373.x.

3. Waxler R. Acromegaly. American Journal of Orthodontics and Dentofacial Orthopedics 2007; 131 (1): 6 DOI: 10.1016/j.ajodo.2006.11.011

4. Capoglu I, Yilmaz AB, Unuvar N, Orbak R, Aksoy H et al. Gingival enlargement in acromegaly. Endocrine 2002; 18 (3): 207-210 DOI: 10.1385/ENDO:18:3:207

5. Lima DL, Montenegro RM, Jr., Vieira AP, Albano MF, Rego DM. Absence of periodontitis in acromegalic patients. Clinical Oral Investigation. 2009;13(2):165-169 DOI: 10.1007/s00784-008-0216-6

6. Bascil S, Serinsoz H, Tutuncu NB. Acromegaly is protective for periodontal tissue - advanced chronic periodontitis is rare in acromegals. Bratislavské Lekarske Listy. 2014;115(9):588-592

7. Al-Kharobi H, El-Gendy R, Devine DA, Beattie J. The role of the insulinlike growth factor (IGF) axis in osteogenic and odontogenic differentiation. Cellular and Molecular Life Sciences. 2014;71(8):1469-1476 DOI: 10.1007/s00018-013-1508-9

8. Li H, Bartold PM, Zhang CZ, Clarkson RW, Young WG et al. Growth hormone and insulin-like growth factor I induce bone morphogenetic proteins 2 and 4: a mediator role in bone and tooth formation? Endocrinology. 1998;139(9):3855-3862 DOI: 10.1210/endo.139.9.6211

9. King GN, Cochran DL. Factors that modulate the effects of bone morphogenetic protein-induced periodontal regeneration: a critical review. Journal of Periodontology. 2002;73(8):925-936 DOI: 10.1902/jop.2002.73.8.925

10. Mi HW, Lee MC, Fu E, Chow LP, Lin CP. Highly efficient multipotent differentiation of human periodontal ligament fibroblasts induced by combined BMP4 and hTERT gene transfer. Gene Therapy. 2011;18(5):452-461 DOI: 10.1038/gt.2010.158

11. Griffiths GS, Curtis MA, Wilton JM. Selection of a filter paper with optimum properties for the collection of gingival crevicular fluid. Journal of Periodontal Research. 1988;23(1):33-8

12. Harb AN, Holtfreter B, Friedrich N, Wallaschofski H, Nauck M et al. Evaluation of the periodontal status in acromegalic patients: a comparative study. ISRN Dentistry. 2012;2012:950486 DOI: 10.5402/2012/950486

13. Ozdemir Y, Keceli HG, Helvaci N, Erbas T, Nohutcu RM. The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients. Endocrine. 2019;66(3):622-633 DOI: 10.1007/s12020-019-02060-2

14. Rao SM, Ugale GM, Warad SB. Bone morphogenetic proteins: periodontal regeneration. North American Journal of Medicine and Science. 2013;5(3):161-168 DOI: 10.4103/1947-2714.109175

15. Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K et al. Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocrine Related Cancer. 2017;24(10):505-518 DOI: 10.1530/ERC-17-0253